Tyra Biosciences Reports Q4 and Full-Year 2025 Financial Results

Focuses on "dabogratinib 3x3" strategy for late-stage trials in LG-UTUC, IR NMIBC and ACH

Published on Mar. 2, 2026

Got story updates? Submit your updates here. ›

Tyra Biosciences, a clinical-stage biotech company focused on FGFR biology, reported its Q4 and full-year 2025 financial results. The company is executing a "dabogratinib 3x3" strategy, developing its lead candidate as a potential first-in-class FGFR3 inhibitor in three late-stage trials for low-grade upper tract urothelial carcinoma (LG-UTUC), intermediate-risk non-muscle invasive bladder cancer (IR NMIBC), and achondroplasia (ACH).

Why it matters

Tyra's focus on FGFR3-driven cancers and skeletal disorders represents a targeted approach to address significant unmet medical needs. The company's precision medicine platform, SNÅP, has enabled the development of oral dabogratinib, which has demonstrated promising efficacy and safety in early trials. Successful execution of the "dabogratinib 3x3" strategy could position Tyra to potentially commercialize a first-in-class FGFR3 inhibitor in multiple blockbuster indications.

The details

Tyra is advancing oral dabogratinib, its lead FGFR3-selective inhibitor, in three Phase 2 trials: SURF303 for LG-UTUC, SURF302 for IR NMIBC, and BEACH301 for ACH. The company exited its metastatic bladder cancer program to focus resources on these three core indications. Interim data from the SURF302 and BEACH301 studies are expected in the first and second half of 2026, respectively.

  • Dose first patient in SURF303 LG-UTUC study - 2026
  • Report initial 3-month complete response data from SURF302 IR NMIBC study - end of 1H 2026
  • Report interim results from BEACH301 ACH safety sentinel cohort - 2H 2026

The players

Tyra Biosciences, Inc.

A clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology.

Todd Harris, Ph.D.

CEO of Tyra Biosciences.

Doug Warner, MD

Chief Medical Officer of Tyra Biosciences.

Alan Fuhrman

Chief Financial Officer of Tyra Biosciences.

Bhavesh Ashar

Chief Operating Officer of Tyra Biosciences.

Heather Faulds

Chief Regulatory Officer of Tyra Biosciences.

Got photos? Submit your photos here. ›

What they’re saying

“At TYRA, we are following the science. The strength of the genetic and biological validation behind FGFR3 gives us conviction to concentrate our resources and strategy around indications where this target plays a central role.”

— Todd Harris, Ph.D., CEO of Tyra Biosciences (PRNewswire)

“Oral dabogratinib reflects years of deliberate molecular optimization to achieve highly selective FGFR3 inhibition with a profile designed to balance potency, safety and convenience.”

— Doug Warner, MD, Chief Medical Officer of Tyra Biosciences (PRNewswire)

“Exiting metastatic bladder cancer allows us to focus financial and operational resources on the three core indications within our "dabogratinib 3x3" strategy that we believe offer the most compelling risk-adjusted opportunities.”

— Alan Fuhrman, Chief Financial Officer of Tyra Biosciences (PRNewswire)

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

Tyra's focus on FGFR3-driven cancers and skeletal disorders through its "dabogratinib 3x3" strategy represents a targeted approach to address significant unmet medical needs. Successful execution of this plan could position the company to potentially commercialize a first-in-class FGFR3 inhibitor in multiple blockbuster indications.